The head of global clinical development for immunology/bone at UCB talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]
Matthew Barton, PhD
Advertisement
Head of global clinical development for immunology/bone at UCB.
Articles by Matthew Barton, PhD
Advertisement
Latest Updated Articles
Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhDPublished: November 7th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug
2
Exploring Complement Inhibition and Claseprubart in CIDP
3
MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease
4
New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease
5
